Cargando…

Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours

BACKGROUND: Adoptive transfer of ex vivo expanded autologous Vγ9Vδ2 T cells may be of therapeutic benefit for cancer because of their potent direct cytotoxicity towards tumour cells, synergistic cytotoxicity when combined with aminobisphosphonates and enhancement of antibody-dependent cell-mediated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nicol, A J, Tokuyama, H, Mattarollo, S R, Hagi, T, Suzuki, K, Yokokawa, K, Nieda, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171009/ https://www.ncbi.nlm.nih.gov/pubmed/21847128 http://dx.doi.org/10.1038/bjc.2011.293

Ejemplares similares

Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings
por: Jonasch, E, et al.
Publicado: (2008)

Phase I trial outcomes in older patients with advanced solid tumours
por: Khan, K H, et al.
Publicado: (2016)

Autologous CIK Cell Immunotherapy in Patients with Renal Cell Carcinoma after Radical Nephrectomy
por: Zhang, Yajing, et al.
Publicado: (2013)

Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours
por: Ahn, H K, et al.
Publicado: (2013)

Skin and Soft Tissue Infections in Patients with Solid Tumours
por: Kofteridis, Diamantis P., et al.
Publicado: (2012)

Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma
por: Patnaik, A, et al.
Publicado: (2014)

Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma
por: Lotem, M, et al.
Publicado: (2004)

Non-V delta 2 gamma delta T lymphocytes as effectors of cancer immunotherapy
por: Fisher, Jonathan, et al.
Publicado: (2014)

Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours
por: Price, T J, et al.
Publicado: (2008)

Contemplating Dichotomous Nature of Gamma Delta T Cells for Immunotherapy
por: Bhat, Jaydeep, et al.
Publicado: (2022)

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours
por: Lankheet, N A G, et al.
Publicado: (2014)

Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours
por: Kerklaan, B Milojkovic, et al.
Publicado: (2015)

Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor
por: Dudek, A Z, et al.
Publicado: (2009)

Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours
por: Freyer, G, et al.
Publicado: (2012)

Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours
por: Mahalingam, D, et al.
Publicado: (2016)

Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours
por: Bahleda, Rastislav, et al.
Publicado: (2015)

Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours
por: Strumberg, D, et al.
Publicado: (2008)

Modulation of human Vα24(+)Vβ11(+) NKT cells by age, malignancy and conventional anticancer therapies
por: Crough, T, et al.
Publicado: (2004)

A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B(12) in Japanese patients with solid tumours
por: Nakagawa, K, et al.
Publicado: (2006)

Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study
por: Isakoff, S J, et al.
Publicado: (2014)

Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours
por: Infante, Jeffrey R, et al.
Publicado: (2018)

A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours
por: Siegel-Lakhai, W S, et al.
Publicado: (2008)

Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours
por: Doi, T, et al.
Publicado: (2012)

Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours
por: Del Conte, G, et al.
Publicado: (2014)

A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia
por: Fonseca, Paula Jiménez, et al.
Publicado: (2016)

Assessment of the efficacy and toxicity of (131)I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumours
por: Nwosu, A C, et al.
Publicado: (2008)

A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours
por: Plummer, R, et al.
Publicado: (2011)

Targeting gamma delta T cells for cancer immunotherapy: bench to bedside
por: Gogoi, Dimpu, et al.
Publicado: (2013)

Engineering Approaches in Human Gamma Delta T Cells for Cancer Immunotherapy
por: Fisher, Jonathan, et al.
Publicado: (2018)

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
por: Papadopoulos, K P, et al.
Publicado: (2017)

Microfluidic technologies for immunotherapy studies on solid tumours
por: Paterson, K., et al.
Publicado: (2021)

A prospective pilot study of two-session Gamma Knife surgery for large metastatic brain tumors
por: Yomo, Shoji, et al.
Publicado: (2012)

Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib
por: Kang, Y-K, et al.
Publicado: (2013)

A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours
por: Penson, R T, et al.
Publicado: (2005)

Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours
por: Kaye, S, et al.
Publicado: (2012)

Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study
por: Michaelson, M D, et al.
Publicado: (2013)

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours
por: Martin, L P, et al.
Publicado: (2012)

Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study
por: Bork, U, et al.
Publicado: (2015)

Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours
por: Martin-Liberal, J, et al.
Publicado: (2014)

Mathematical and numerical methods for the nonlinear hyperbolic propagation problem delta$^{2}$GAMMA/delta.t$^{2}$ = (delta/delta.z)((delta.GAMMA(delta.t)(delta.GAMMA/delta.z)): a preliminary treatment of collective space
por: Funk, U N, et al.
Publicado: (1982)

Cannot write session to /tmp/vufind_sessions/sess_ep5tk9bms1hm7qg445getf9pah